Effectiveness of the PLAC Test for Lp-PLA2 Activity has been demonstrated across multiple clinical trials and patient populations.

  • The greater the Lp-PLA2 activity, the greater the risk for fatal and nonfatal CHD events (Figure 1)
  • PLAC activity above 225 nmol/min/mL identifies patients at increased risk for CHD events across patient type and population (Figure 2)
  • Absolute risk of CHD events is 2.1 times greater with a positive PLAC Test (Figure 2)
Lp-PLA2 activity and CHD risk3
Positive correlation between Lp-PLA2 activity and risk for coronary heart disease
Figure 1
Risk for CHD events by patient type4
Increased absolute risk for certain sub-populations
Figure 2

The PLAC Test for Lp-PLA2 Activity has a validated cut point of 225 nmol/min/mL

The PLAC Test for Lp-PLA2 Activity incorporates a validated, easy-to-use cut point of 225 nmol/min/mL.


HEALTHCARE PROFESSIONALS

The PLAC Test for Lp-PLA2 Activity provides physicians with additional prognostic information previously unavailable with traditional risk factors.

LEARN MORE

LABORATORY PROFESSIONALS

The PLAC Test for Lp-PLA2 Activity offers enhanced cardiovascular risk assessment from your laboratory.

LEARN MORE